Accelerating Cancer Therapeutics (ACT)
Accelerating Cancer Therapeutics (ACT) is a therapeutic development accelerator program focused on providing funding, education, partnership, and mentorship to Columbia Investigators, with a goal of advancing novel cancer therapies from the lab towards the clinic. Advice and project guidance will be provided by a steering committee of academic and industry experts in the field of drug development. Researchers are also encouraged to submit their funded research outcomes for publication in academic journals, as usual.
- Applications open:
- Thursday, Oct. 6, 2022
- Applications due:
- Tuesday, Nov. 15, 2022
- Cohort announced:
- Wednesdays, 4-6:30PM, Jan - May
- Pitch Day:
Cumulative Success Metrics (ACT)
- 5 cycles administered
- 29 applications received
- 28 teams admitted to/went through accelerator
- 19 awards given
- Over $995K in funding awarded by ACT to teams
- $403K in funding awarded to teams by external sources
2019-2020 Founders' Spotlights
Student Venture Associate Kush Mody interviewed cohort member Dr. Juan Arriaga of Meta Test. Based on research from the lab of Dr. Cory Abate-Shen which specializes in prostate cancer mouse models, Meta Test is a gene signature that will discern which patients are likely to develop metastases.
Student Venture Associate Grace Kim had a chance to virtually sit down with cohort member Dr. Yiping Han of FAP. Dr. Han's lab studies the role of bacterial pathogenesis in cancer.